Cargando…
Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis
BACKGROUND: Neoadjuvant radiotherapy (NRT) for resectable retroperitoneal sarcoma (RPS) has been shown to be systematically feasible. Whether NRT has equivalent or better clinical effects compared to surgery alone for RPS patients remains controversial. METHODS: We performed a systematic literature...
Autores principales: | Li, Xiangji, Dong, Ruihan, Xiao, Mengmeng, Min, Li, Luo, Chenghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795731/ https://www.ncbi.nlm.nih.gov/pubmed/36578082 http://dx.doi.org/10.1186/s13014-022-02159-3 |
Ejemplares similares
-
Adjuvant therapy for retroperitoneal sarcoma: a meta-analysis
por: Li, Xiangji, et al.
Publicado: (2021) -
The Janus-faced role of TRPM2-S in retroperitoneal liposarcoma via increasing ROS levels
por: Li, Xiangji, et al.
Publicado: (2022) -
Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas—Looking Forward
por: Istl, Alexandra C., et al.
Publicado: (2022) -
Clinical outcomes of tissue expanders on adjuvant radiotherapy of resected retroperitoneal sarcoma
por: Yu, Jeong Il, et al.
Publicado: (2016) -
Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma
por: Palm, Russell F., et al.
Publicado: (2020)